Adaptive Biotechnologies (ADPT) News Today $8.27 -0.06 (-0.72%) Closing price 04:00 PM EasternExtended Trading$8.28 +0.01 (+0.06%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Adaptive Biotechnologies (NASDAQ:ADPT) Earns "Overweight" Rating from Piper SandlerPiper Sandler restated an "overweight" rating and issued a $11.00 price target (up from $7.00) on shares of Adaptive Biotechnologies in a research note on Thursday.February 21 at 1:13 PM | marketbeat.comAdaptive Biotechnologies price target raised to $11 from $7 at Piper SandlerFebruary 20 at 10:20 AM | markets.businessinsider.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Chad M. Robins Sells 158,921 SharesAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 158,921 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $8.46, for a total transaction of $1,344,471.66. Following the completion of the transaction, the chief executive officer now directly owns 2,576,701 shares in the company, valued at $21,798,890.46. This represents a 5.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 19 at 8:49 PM | marketbeat.comChad M. Robins Sells 211,160 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) StockAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) CEO Chad M. Robins sold 211,160 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $8.50, for a total value of $1,794,860.00. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares in the company, valued at approximately $21,901,958.50. This trade represents a 7.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.February 19 at 8:49 PM | marketbeat.comChad M. Robins Sells 158,921 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) StockFebruary 19 at 4:15 AM | insidertrades.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by DDD Partners LLCDDD Partners LLC lessened its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 91.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 64,747 shares of the company's stock afterFebruary 17, 2025 | marketbeat.comScotiabank Increases Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $12.00February 16, 2025 | americanbankingnews.comAdaptive Biotechnologies (NASDAQ:ADPT) Hits New 1-Year High on Analyst UpgradeFebruary 15, 2025 | americanbankingnews.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 7.9% After Analyst UpgradeFebruary 15, 2025 | americanbankingnews.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.9% Following Analyst UpgradeAdaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.9% Following Analyst UpgradeFebruary 14, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High After Analyst UpgradeAdaptive Biotechnologies (NASDAQ:ADPT) Sets New 52-Week High Following Analyst UpgradeFebruary 14, 2025 | marketbeat.comADPT stock soars to 52-week high, reaching $8.33February 13, 2025 | msn.comScotiabank Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock PriceScotiabank increased their target price on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a research report on Thursday.February 13, 2025 | marketbeat.comAdaptive Biotechnologies price target raised to $12 from $10 at ScotiabankFebruary 13, 2025 | markets.businessinsider.comLegato Capital Management LLC Has $1.11 Million Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Legato Capital Management LLC cut its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 184,668 shares of the comFebruary 13, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)February 12, 2025 | markets.businessinsider.comAdaptive Biotechnologies Q4 revenue beats estimates, loss narrower than expectedFebruary 12, 2025 | msn.comAdaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvementsFebruary 11, 2025 | msn.comAdaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call TranscriptFebruary 11, 2025 | seekingalpha.comAdaptive Biotechnologies (NASDAQ:ADPT) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPSAdaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative return on equity of 62.06% and a negative net margin of 110.13%. During the same period in the previous year, the business posted ($0.30) earnings per share.February 11, 2025 | marketbeat.comAdaptive Biotechnologies reports Q4 EPS (23c), consensus (24c)February 11, 2025 | markets.businessinsider.comAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 11, 2025 | globenewswire.comSumitomo Mitsui Trust Group Inc. Sells 900,747 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Sumitomo Mitsui Trust Group Inc. decreased its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 11.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,833,137 shares of the company's stock after seFebruary 11, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Trading Down 5.2% - Time to Sell?Adaptive Biotechnologies (NASDAQ:ADPT) Trading Down 5.2% - Time to Sell?February 10, 2025 | marketbeat.comAdaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Report Preview: What To Look ForFebruary 10, 2025 | finance.yahoo.comJennison Associates LLC Has $1.07 Million Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Jennison Associates LLC lessened its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 23.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 177,858 shares of the company's stock after selling 53,673 shares during the quFebruary 7, 2025 | marketbeat.comAdaptive Biotechnologies to Participate in Upcoming Investor ConferencesFebruary 5, 2025 | globenewswire.comAdaptive Biotechnologies (NASDAQ:ADPT) Trading 9.8% Higher - Should You Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 9.8% - Here's What HappenedFebruary 5, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Down 4.6% - Here's What HappenedAdaptive Biotechnologies (NASDAQ:ADPT) Shares Down 4.6% - Should You Sell?February 4, 2025 | marketbeat.comAdaptive Biotechnologies (ADPT) Expected to Announce Quarterly Earnings on TuesdayAdaptive Biotechnologies (NASDAQ:ADPT) will be releasing earnings after the market closes on Tuesday, February 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=658439)February 4, 2025 | marketbeat.comThe 5.4% return this week takes Adaptive Biotechnologies' (NASDAQ:ADPT) shareholders one-year gains to 99%January 29, 2025 | finance.yahoo.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Price Expected to Rise, The Goldman Sachs Group Analyst SaysThe Goldman Sachs Group boosted their price objective on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the company a "neutral" rating in a research report on Tuesday.January 28, 2025 | marketbeat.comWhy Adaptive Biotechnologies Corporation (ADPT) Is Skyrocketing NowJanuary 24, 2025 | msn.comWhy Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now?January 23, 2025 | msn.comAdaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025January 22, 2025 | globenewswire.comAdaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 1-Year High - Time to Buy?January 22, 2025 | marketbeat.comAdaptive Biotechnologies stock hits 52-week high at $7.47January 21, 2025 | msn.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 7.1% - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Trading 7.1% Higher - Here's What HappenedJanuary 21, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Up 17.6% - Time to Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 17.6% - Here's WhyJanuary 15, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% - What's Next?January 14, 2025 | marketbeat.comAdaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer PatientsJanuary 14, 2025 | globenewswire.comBarclays PLC Boosts Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Barclays PLC lifted its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 149.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 230,177 shares of the company'sJanuary 14, 2025 | marketbeat.comCathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its WorkforceJanuary 11, 2025 | benzinga.comAdaptive Biotechnologies announces lab fee schedule rate of $2,007 for clonoSEQJanuary 9, 2025 | markets.businessinsider.comAdaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025January 7, 2025 | globenewswire.comAdaptive Biotechnologies (NASDAQ:ADPT) Sees Strong Trading Volume - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Sees Large Volume Increase - Here's WhyJanuary 6, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Sets New 1-Year High - Still a Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Sets New 12-Month High - Here's What HappenedJanuary 3, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Teladoc (TDOC)January 3, 2025 | markets.businessinsider.comAdaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.3% - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.3% - Should You Buy?January 2, 2025 | marketbeat.com Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address ADPT Media Mentions By Week ADPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADPT News Sentiment▼0.340.60▲Average Medical News Sentiment ADPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADPT Articles This Week▼124▲ADPT Articles Average Week Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TG Therapeutics News Today Krystal Biotech News Today SpringWorks Therapeutics News Today Biohaven News Today Recursion Pharmaceuticals News Today PTC Therapeutics News Today Organon & Co. News Today Ultragenyx Pharmaceutical News Today Alvotech News Today Avidity Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADPT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADPT Stock Alerts